ES2462921T3 - Sales de lercanidipino - Google Patents

Sales de lercanidipino Download PDF

Info

Publication number
ES2462921T3
ES2462921T3 ES05776228.8T ES05776228T ES2462921T3 ES 2462921 T3 ES2462921 T3 ES 2462921T3 ES 05776228 T ES05776228 T ES 05776228T ES 2462921 T3 ES2462921 T3 ES 2462921T3
Authority
ES
Spain
Prior art keywords
lercanidipine
crystalline
salt
besylate
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05776228.8T
Other languages
English (en)
Spanish (es)
Inventor
Amedeo Leonardi
Gianni Motta
Markus Von Raumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Recordati Ireland Ltd
Recordati Industria Chimica e Farmaceutica SpA
Original Assignee
Recordati SA
Recordati Ireland Ltd
Recordati Industria Chimica e Farmaceutica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA, Recordati Ireland Ltd, Recordati Industria Chimica e Farmaceutica SpA filed Critical Recordati SA
Application granted granted Critical
Publication of ES2462921T3 publication Critical patent/ES2462921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES05776228.8T 2004-08-24 2005-08-22 Sales de lercanidipino Expired - Lifetime ES2462921T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
US604149P 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (1)

Publication Number Publication Date
ES2462921T3 true ES2462921T3 (es) 2014-05-26

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05776228.8T Expired - Lifetime ES2462921T3 (es) 2004-08-24 2005-08-22 Sales de lercanidipino

Country Status (19)

Country Link
US (1) US7683179B2 (https=)
EP (1) EP1799644B1 (https=)
JP (1) JP2008510754A (https=)
KR (1) KR20070045351A (https=)
CN (1) CN101048379A (https=)
AR (1) AR050467A1 (https=)
AU (1) AU2005276619B2 (https=)
BR (1) BRPI0514606A (https=)
CA (1) CA2575078A1 (https=)
EA (1) EA011773B1 (https=)
ES (1) ES2462921T3 (https=)
IL (1) IL180905A0 (https=)
MX (1) MX2007002141A (https=)
NO (1) NO20071515L (https=)
NZ (1) NZ553127A (https=)
PE (1) PE20060629A1 (https=)
TW (1) TW200613275A (https=)
WO (1) WO2006021397A1 (https=)
ZA (1) ZA200702364B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
RU2008151724A (ru) 2006-06-12 2010-07-20 Новартис АГ (CH) Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
IN2009DN05509A (https=) * 2007-03-14 2010-04-30 Teva Pharma
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
CA2706775A1 (en) 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN102186351A (zh) * 2008-08-01 2011-09-14 医药公司 药物组合物和用于稳定药物组合物的方法
WO2010014727A1 (en) * 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for producing low impurity concentrations of the same
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2539313A2 (en) * 2010-03-29 2013-01-02 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
JPWO2023219106A1 (https=) * 2022-05-10 2023-11-16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
KR20070045351A (ko) 2007-05-02
EA200700492A1 (ru) 2007-08-31
AR050467A1 (es) 2006-10-25
CA2575078A1 (en) 2006-03-02
NZ553127A (en) 2009-07-31
WO2006021397A8 (en) 2006-04-27
MX2007002141A (es) 2007-04-27
AU2005276619B2 (en) 2009-04-30
ZA200702364B (en) 2008-09-25
US20060047125A1 (en) 2006-03-02
IL180905A0 (en) 2007-07-04
WO2006021397A1 (en) 2006-03-02
EP1799644A1 (en) 2007-06-27
EP1799644B1 (en) 2014-02-12
JP2008510754A (ja) 2008-04-10
NO20071515L (no) 2007-05-22
TW200613275A (en) 2006-05-01
BRPI0514606A (pt) 2008-06-17
AU2005276619A1 (en) 2006-03-02
EA011773B1 (ru) 2009-06-30
PE20060629A1 (es) 2006-08-11
US7683179B2 (en) 2010-03-23
CN101048379A (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
ES2462921T3 (es) Sales de lercanidipino
US12172960B2 (en) Organic compound salts
ES2334678T3 (es) Nueva foprma cristalina de hidrocloruro de lercanidipino y procedimiento para su preparacion.
US6852737B2 (en) Crude and crystalline forms of lercanidipine hydrochloride
AU2002327924A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
CN100494175C (zh) 盐酸乐卡地平的溶剂合物和盐酸乐卡地平的晶形
RU2146672C1 (ru) Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
CA2399459C (en) Novel crude and crystalline forms of lercanidipine hydrochloride
HK40105022A (en) Crystalline hydrobromide salt of 5-meo-dmt
CA2380202A1 (en) Novel crude and crystalline forms of lercanidipine hydrochloride
HK1140487B (en) Pharmaceutical compositions containing crystalline form (i) of lercanidipine hydrochloride
KR20130033243A (ko) 아데포비어 디피복실의 공결정
HK1067123B (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and processes for their preparation